An interventional study of pentoxifylline in Hemodialysis Complication, sponsored by Alexandria University. Status unknown at 1 site in Egypt. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.
Sponsored by Alexandria University · Not applicable, Interventional, and Treatment
The primary goal of this clinical trial is to evaluate the promoting effect of pentoxifylline on anemia correction in hemodialysis patients, and involvement of the hypoxia-inducible factor-2 alpha. While, the secondary aim is to evaluate the effect of pentoxifylline on inflammation, hepcidin and other markers of iron homeostasis in these patients. Participants in this trial will be selected to be age and sex ratio matched and will be randomly assigned into two groups. Patients in group I will receive their regular doses of erythropoietin stimulating agents and other routine treatments plus 400 mg pentoxifylline tablets twice daily with meals for 6 months. While, patients in group II will receive their regular doses of erythropoietin stimulating agents and other routine treatments.
1,733 studies on the registry are indexed under Anemia; 246 are open to participants now.
This study's planned enrollment of 80 is below the median of 94 across 1,291 interventional studies indexed under Anemia.
Browse Anemia studies →Alexandria University is the lead sponsor of 569 studies on the registry; 125 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: pentoxifylline
400 mg pentoxifylline tablets twice daily with meals for 6 months
Variation in Hemoglobin (Hb) levels
Time frame: 6 months
Variation in Hypoxia inducible factor-2 alpha (HIF-2α) levels
Time frame: 6 months
Variation in Transforming growth factor β1 (TGF-β1) levels
Time frame: 6 months
Variation in erythropoietin stimulating agents' (ESAs) doses
Time frame: 6 months
Variation in ESA resistance index (ESA Dose/kg/Week/Hb)
Time frame: 6 months
Variation in different inflammatory markers levels
Including levels of C-reactive protein (CRP) and Interleukin 6 (IL-6)
Time frame: 6 months
Variation in hepcidin hormone levels
Time frame: 6 months
Variation in different parameters for iron status evaluation
Including serum levels of ferritin, iron and total iron binding capacity (TIBC)
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexandria University